GTC Solid Tumor Fusion/Expression Profile

This test provides clinically relevant information on translocations and expression of cancer-specific genes.  This assay is designed to detect various translocations involving more than 60 genes, including ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, BRAF, CIC, EWSR1, PD-L1, and others.  This also covers screening for sarcoma translocations and aids in sarcoma diagnosis and classification.  In addition, the expression of genes of clinical relevance is reported including MYC, PD-L1, and others.

 


Download our Test Requisition

Access Requisition

Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.


Do you want to download the Requisition?

DOWNLOAD SAMPLE TEST for Solid Fusion Expression

 

-Breaking News!-

Why Solid Tumor Fusion/Expression Profile Test is Important:

On Monday, November 26, 2018 FDA Approved* larotrectinib, a targeted therapy for patients with solid tumors harboring an NTRK gene fusion, regardless of tumor type.

This approved therapy is for patients with advanced solid tumors containing what’s called an NTRK gene fusion, a hybrid of two genes that can promote uncontrolled cell growth. Cancers of the thyroid, lung, and head and neck, among others, can be caused by the defect. The drug is for patients whose cancer has spread or who would experience severe complications by undergoing surgery and have no satisfactory alternatives.

On the other hand, the therapy faces a huge challenge: Finding patients who might benefit. Only an estimated 2,000 to 3,000 people a year in the United States develop NTRK-related cancers.

“The million-dollar question is: How do you know you have the fusion that the drug treats?”

The mutation occurs in less than 1 percent of most solid tumor types, but is common in malignancies such as adult salivary cancer and infantile fibrosarcoma. The only way to find the mutation is through much broader genetic tumor testing.

Genomic Testing Cooperative (GTC) offers the comprehensive next-generation sequencing (NGS) Solid Tumor Fusion / Expression profile specifically testing for fusions in NTRK1, NTRK2, and NTRK3.

*Read about the approval  on Washington Post and Reuters


Specimen Requirements:

  • FFPE: 1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative. Please circle tumor for microdissection. Alternatively, the FFPE block can be sent for tumor circling and cutting at our laboratory.

Shipping:

Ship using cold pack. The cold pack should not directly contact Blood or BM specimen. Ship As soon as sample collected with overnight delivery.

Turn Around Time: 7 days

Tested Genes

Loading…